纯度 | >95%SDS-PAGE. |
种属 | Human |
靶点 | SEC13 |
Uniprot No | P55735 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 1-322aa |
氨基酸序列 | MGSSHHHHHH SSGLVPRGSHMVSVINTVDT SHEDMIHDAQ MDYYGTRLAT CSSDRSVKIF DVRNGGQILI ADLRGHEGPV WQVAWAHPMY GNILASCSYD RKVIIWREEN GTWEKSHEHA GHDSSVNSVC WAPHDYGLIL ACGSSDGAIS LLTYTGEGQW EVKKINNAHT IGCNAVSWAPAVVPGSLIDH PSGQKPNYIK RFASGGCDNL IKLWKEEEDG QWKEEQKLEA HSDWVRDVAW APSIGLPTST IASCSQDGRV FIWTCDDASS NTWSPKLLHK FNDVVWHVSW SITANILAVS GGDNKVTLWK ESVDGQWVCI SDVNKGQGSV SASVTEGQQN EQ |
预测分子量 | 38 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组SEC13蛋白的3篇参考文献及其摘要概括:
---
1. **文献名称**: "Structural basis for the assembly of the nuclear pore complex"
**作者**: Hoelz A. et al.
**摘要**: 该研究通过X射线晶体学解析了SEC13与SEH1蛋白形成的复合体结构,揭示了其在核孔复合体支架组装中的关键作用。重组表达的SEC13蛋白被用于结构分析,证实其β-propeller结构介导了与其他核孔蛋白的相互作用。
2. **文献名称**: "COPII-coated vesicle formation reconstituted with purified components"
**作者**: Matsuoka K. et al.
**摘要**: 作者利用重组表达的SEC13-SEC31异源二聚体,结合其他COPII组分(如Sar1和SEC23/24),在体外重构了COPII囊泡的形成过程。研究证明SEC13-SEC31对囊泡出芽的机械性能调控至关重要。
3. **文献名称**: "Expression and functional characterization of recombinant SEC13 in endoplasmic reticulum export"
**作者**: Kim S.J. & Lee M.C.
**摘要**: 该文献报道了在大肠杆菌中高效表达并纯化重组SEC13蛋白的方法,并通过体外结合实验证实其与SEC31的相互作用依赖于特定的结构域。功能研究表明,SEC13缺失会显著抑制内质网到高尔基体的货物运输。
---
以上文献涵盖了SEC13的结构、功能及其在膜运输系统中的机制研究,均涉及重组蛋白技术的应用。如需扩展,可进一步检索近年冷冻电镜相关研究(如SEC13在核孔复合体动态组装中的研究)。
SEC13 is a conserved eukaryotic protein integral to intracellular vesicle trafficking, primarily known for its role in the COPII (coat protein complex II) complex. This complex mediates the transport of newly synthesized proteins and lipids from the endoplasmic reticulum (ER) to the Golgi apparatus. SEC13. along with SEC31. forms the outer layer of the COPII coat, facilitating membrane curvature and vesicle budding. Structurally, SEC13 contains WD40 repeat domains that enable protein-protein interactions critical for COPII assembly.
Recombinant SEC13 refers to the protein produced via genetic engineering in heterologous expression systems (e.g., bacteria, insect cells, or mammalian cells). Its recombinant form retains functional properties, allowing researchers to study COPII dynamics, ER-Golgi trafficking mechanisms, and membrane remodeling in vitro. SEC13 is also implicated in nuclear pore complex (NPC) assembly, highlighting its dual cellular roles. Dysregulation of SEC13 has been linked to developmental disorders and diseases, such as cranio-lenticulo-sutural dysplasia and certain cancers, underscoring its biomedical relevance.
In research, recombinant SEC13 is utilized for structural studies (e.g., crystallography, cryo-EM), biochemical assays (e.g., COPII reconstitution), and drug screening targeting trafficking pathways. Its production enables exploration of COPII-related pathologies and potential therapeutic interventions. Additionally, SEC13 homologs in model organisms (e.g., yeast) have provided foundational insights into conserved trafficking mechanisms. Overall, recombinant SEC13 serves as a vital tool for dissecting cellular transport processes and their disease connections.
×